Transplant Diagnostics Market was Led by the Molecular Assays Category

The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.

To learn more about this report: https://bit.ly/3vek5es

This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases. 

Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.

On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.

The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.

Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.

North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.

Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.

There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.

Read More

Oligonucleotide Synthesis Market is Ultimately Generating $2.8 Billion in Revenue by 2023

Valued at $1.5 billion in 2017, the oligonucleotide synthesis market size is predicted to progress with a 10.8% CAGR during the forecast period 2018–2023, ultimately generating $2.8 billion in revenue by 2023. By definition, oligonucleotide synthesis is the artificial creation of oligonucleotides, which are short DNA or RNA fragments.

On the basis of offering, reagents and consumables, synthesized oligonucleotides, and equipment are the three market categories. Among these, synthesized oligonucleotides held the largest revenue share (76.3%) in 2017 and is also predicted to grow the fastest during the forecast period, at an 11.1% CAGR. The increase in contract manufacturing of DNAs and RNAs is expected to escalate the demand for synthesized oligonucleotides. Similarly, when segmented by application, the oligonucleotide synthesis market can be categorized into diagnostics, research, and therapeutics.

To Learn more About this report@ http://bit.ly/2UrgrJx

Among all, the research category led the market in 2017 and is expected to be the fastest growing (11.1% CAGR) category. This pays credence to the finding that of all the end users of synthetic oligonucleotides, including diagnostic laboratories, pharmaceutical and biotechnology companies, academic research institutes, and others, academic research institutes dominated the oligonucleotide synthesis market in 2017 with 40.4% revenue share. This further substantiates the fact that increasing research activities in the field is one of the key growth drivers of the market.

In addition, several new products have come in the oligonucleotide synthesis market, such as protecting amino groups, synthesizers with high throughput, and coupling reagents. Similarly, the development of the microarray technology is aiding the production of oligonucleotides for the diagnosis and treatment of diseases. Along with making the nucleotide assembly method efficient and correcting errors in synthesized enzymes, such developments are also helping in the steady progress of the market.

Now, the oligonucleotide R&D is itself being bolstered by growing government support in the form of funding and other initiatives. The U.S. government invested about $820 million in synthetic biology R&D between 2008 and 2014. Similarly, as per SynbiCITE an England-based organization, the U.K government invested over $400 million during 2009–2016 for establishing three training centers and six research institutes dedicated to synthetic biology. Thus, with favorable government attitude toward providing people with better levels of healthcare, the oligonucleotide synthesis market is predicted to continue on the path to prosperity.

Hence, it is clear that the increase in research and development in the synthetic biology field will further the market advance.

Read More